• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine, Inc. - Common Stock (NQ:EDIT)

    2.805 +0.005 (+0.18%)
    Streaming Delayed Price Updated: 2:51 PM EDT, Jun 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,311,739
    Open 2.790
    Bid (Size) 2.800 (4,200)
    Ask (Size) 2.810 (2,700)
    Prev. Close 2.800
    Today's Range 2.795 - 2.915
    52wk Range 1.660 - 4.537
    Shares Outstanding 81,632,619
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
    One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026. 
    Via The Motley Fool
    News headline image
    Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
    From Editas Medicine, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +36.8%
    +36.8%
    1 Month
    -8.9%
    -8.9%
    3 Month
    +20.9%
    +20.9%
    6 Month
    +26.9%
    +26.9%
    1 Year
    +24.7%
    +24.7%

    More News

    Read More
    News headline image
    Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Editas Medicine Announces Proposed Public Offering
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Announces First Quarter 2026 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Is Editas Medicine Going to $0? ↗
    Via The Motley Fool
    News headline image
    Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine to Participate in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas (EDIT) Q2 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
    Via Chartmill
    News headline image
    Editas Medicine Announces Third Quarter 2025 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
    Via TokenRing AI
    Topics Artificial Intelligence Climate Change Intellectual Property
    News headline image
    Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗
    Via Benzinga
    News headline image
    Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗
    Via Chartmill
    News headline image
    Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
    From Editas Medicine, Inc.
    Via GlobeNewswire
    News headline image
    My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗
    Via Benzinga
    News headline image
    Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
    Via Benzinga
    News headline image
    Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
    From Editas Medicine, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Editas Medicine, Inc. - Common Stock publicly traded?
    Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
    What exchange does Editas Medicine, Inc. - Common Stock trade on?
    Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
    The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
    What is the current price of Editas Medicine, Inc. - Common Stock?
    The current price of Editas Medicine, Inc. - Common Stock is 2.805
    When was Editas Medicine, Inc. - Common Stock last traded?
    The last trade of Editas Medicine, Inc. - Common Stock was at 06/25/26 02:51 PM ET
    What is the market capitalization of Editas Medicine, Inc. - Common Stock?
    The market capitalization of Editas Medicine, Inc. - Common Stock is 228.98M
    How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
    Editas Medicine, Inc. - Common Stock has 229M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.